פרבסטאטין טבע 40 מג

Χώρα: Ισραήλ

Γλώσσα: Εβραϊκά

Πηγή: Ministry of Health

Δραστική ουσία:

PRAVASTATIN SODIUM

Διαθέσιμο από:

TEVA ISRAEL LTD

Φαρμακολογική κατηγορία (ATC):

C10AA

Φαρμακοτεχνική μορφή:

טבליה

Σύνθεση:

PRAVASTATIN SODIUM 40 MG

Οδός χορήγησης:

פומי

Τρόπος διάθεσης:

מרשם נדרש

Κατασκευάζεται από:

TEVA ISRAEL LTD, ISRAEL

Θεραπευτική ομάδα:

HMG COA REDUCTASE INHIBITORS

Θεραπευτικές ενδείξεις:

Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *Primary prevention of coronary events: In hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarcton. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *Secondary prevention of cardiovascular events: Atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute coronary events. Myocardial infa

Ημερομηνία της άδειας:

2022-01-31

Φύλλο οδηγιών χρήσης

Pravastatin Teva MW 07/2023 Notification
(
) "
–
1986
20
"
:
20
"
Pravastatin sodium 20 mg
40
"
:
40
"
Pravastatin sodium 40 mg
2
"
"
6
-
."
"
.
.
.
,
.
.
.
18
.
1
.
?
•
.
•
.
•
-
,
.
:
•
""
""
.
,
,
.
)
(
.
.
,)
(
,
,) (
,
.
,)
(
.
.
•
,
)
(
.
.
,
,
,
,
.
:
Pravastatin Teva MW 07/2023 Notification
(
HMG-CoA
.)
)
(
.
2
. :
•
)(
(
6
-
"
"
)
.
•
.
•
(
"
"
.)
,
:
•
,
(
)
,)
(
(
4
–
"
.)"
•
.
•
70
.
•
.
•
-
.)
(
•
.
•
(
HMG-CoA
)
(
)
.
•
–
.
•
(
)
.
•
-
7
(
)
.
(
)
.
,
.
.
.
.
.
,
:
•
.
,
.
,
,
.
,
.
.
, , , .
:
•
,
(
)
Pravastatin Teva MW 07/2023 Notification
(
(
B3
)
)
-
.
•
(
,
)
,
.
,
3
"
?
"
.
•
,
(
)
.
,
.
.
,
.)
(
4
"
"
.
•
"
K
"
,
K
K
.
:
•
(
[
]
)
•
(
)
•
(
)
•
(
)
.
,
,
.
,
.
:
•
,)
(
.
•
,
,
,
( ,
)
.
.
•
,
.
,
.
.
.
•
.
,
.
•
-
23
"
.
Pravastatin Teva MW 07/2023 Notification
3
. ?
.
.
,
. .
:
•
:
10-40
. ,
,
"
•
:
40
,
,"
.
•
.
.
,
,
.
.
.
.
/
/
20
:"
.
10
,"
10
"
.
40
:"
.
:
,
,
,
,
,
.
.
•
(
)
,
,
.
.
,
.
,
.
.
.
,
. ! .
.
. ,
4
.
,
.
.
.
Pravastatin Teva MW 07/2023 Notification
:
•
,
,
,
.
,
.
.
•
/
. :
•
,
,
,
.
•
,
)
(
,
,
.
:
. :
(
1
100
:)
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
)
(
•
,
(
)
•
•
(
1
10,000
:)
•
,
,
.)
(
•
(
lupus erythematous-like syndrome
.)
•
,
(
)
•
)
(
.
•
.
•
(
)
,
.
.
Pravastatin Teva MW 07/2023 Notification (
) :
•
. ,
•
:
(
5.6
/
,
BMI
<
30
/"
2
,
.)
,
•
.)
(
•
.
•
,
(
.)
•
.)
(
,
,
.
( :)
•
•
•
•
/
.
•
:
,
.
. , ,
.
"
(
"
www.health.gov.il
)
,
-
:
https://sideeffects.health.gov.il
5
. ?
•
!
/
.
.
•
(exp. date)
.
.
• ,
-
25°C
. .
•
.
.
.
6
.
: ,
Lactose monohydrate, crospovidone, magnesium stearate.
:
20 : "
-
.
,
30
(
)
.
40 : "
-
,
,
"
P
."
30
(
)
.
Pravastatin Teva MW 07/2023 Notification :
"
,
'
124
,
.
2023
.
:
20
"
124.64.30379
40
"
124.65.30380
.
,
.
,